Vanda Pharmaceuticals Reports First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- FedEx pilots ratify new collective bargaining agreement
- The real reason Meta shares are surging has nothing to do with its new AI model
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
Vanda Pharma (VNDA) Buy Rating and $15 PT Reiterated - Jefferies
May 5, 2016 9:45 AM EDTJefferies analyst, Chris Howerton, maintained his Buy rating and $15 PT after Vanda (NASDAQ: VNDA) reported a strong 1Q with 3 takeaways:
1) Hetlioz - strong 1Q sales (~$16.2M vs Jef est. of ~$15.4M) suggt'ng ~80 net patient adds in our model; EU launch in 3Q16 mgmt... More
Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 7c
May 4, 2016 5:31 PM EDTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of ($0.17), $0.07 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $32.57 million.
2016 Financial Guidance
Vanda reiterates its prior 2016 financial guidance and expects to achieve the following... More
